title: Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis.
abstract: OBJECTIVE
  The purpose of this work was to assess the costs of 4 neonatal screening strategies for cystic fibrosis in relation to health effects. In each strategy, the first test was the measurement of serum concentration of immunoreactive trypsin. The second step consisted of either a second immunoreactive trypsin test (strategy 1) or a multiple mutation analysis (strategy 2). In strategies 3 and 4, a third step was added to strategy 2: a second immunoreactive trypsin test (strategy 3) or an extended mutation analysis of the cystic fibrosis gene, that is, a denaturing gradient gel electrophoresis analysis (strategy 4).
  
  
  METHODS
  We conducted an economic-modeling exercise in the Netherlands based on published data and expert opinions. Subjects were a hypothetical cohort of 200 000 neonates, the approximate number of children born annually in the Netherlands, and we assessed the costs and number of life-years gained as a result of neonatal screening for cystic fibrosis. The costs and effects of changes in reproductive decisions because of neonatal screening were also assessed.
  
  
  RESULTS
  Immunoreactive trypsin + immunoreactive trypsin had the most favorable cost-effectiveness ratio of 24,800 euro per life-year gained. Immunoreactive trypsin + DNA + denaturing gradient gel electrophoresis achieved more health effects than immunoreactive trypsin + DNA + immunoreactive trypsin at lower cost. The incremental costs per life-year gained of the immunoreactive trypsin + DNA + denaturing gradient gel electrophoresis strategy compared with the immunoreactive trypsin + immunoreactive trypsin strategy were 130,700 euro, whereas the incremental costs of the immunoreactive trypsin + DNA strategy compared with the immunoreactive trypsin + DNA + denaturing gradient gel electrophoresis strategy were 2,154,300 euro. When changes in reproductive decisions as a result of neonatal screening are also taken into account, neonatal screening for cystic fibrosis may lead to financial savings of approximately 1.8 million euro annually, depending on the screening strategy used.
  
  
  CONCLUSIONS
  Cystic fibrosis screening for neonates is a good economic option, and positive health effects can also be expected. Immunoreactive trypsin + immunoreactive trypsin and immunoreactive trypsin + DNA + denaturing gradient gel electrophoresis are the most cost-effective strategies.
authors.affiliation: Netherlands Organization for Applied Scientific Research, Quality of Life, Leiden, Netherlands. elske.vandenakker@tno.nl
authors.forename: M Elske
authors.initials: ME
authors.lastname: van den Akker-van Marle
authors.forename: Hinke M
authors.initials: HM
authors.lastname: Dankert
authors.forename: Paul H
authors.initials: PH
authors.lastname: Verkerk
authors.forename: Jeannette E
authors.initials: JE
authors.lastname: Dankert-Roelse
mesh_terms: D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D004252:DNA Mutational Analysis; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D007118:Immunoassay; D007231:Infant, Newborn; D015997:Neonatal Screening / Q000191:economics* / Q000379:methods; D014357:Trypsin / Q000097:blood
chemical_list: D014357:Trypsin